Drug intelligence / Profile preview

CssBA

Development stage: Phase 2
Lead developer: PATH Vaccine Solutions
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

CssBA is a recombinant protein vaccine candidate designed to prevent infection by enterotoxigenic Escherichia coli (ETEC), specifically targeting the CS6 colonization factor. It is a heterodimeric fusion protein composed of components derived from the ETEC CS6 subunits CssA and CssB. The vaccine elicits strong IgG and IgA anti-CS6 antibody responses in preclinical models and has been evaluated in Phase 1 clinical trials for safety and immunogenicity when administered intramuscularly or intradermally, with or without adjuvant (such as dmLT). The lead developer is PATH Vaccine Solutions.

Other names: CssBA

Targets

Sulfatide

Beyond the preview

Go deeper on CssBA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CssBA.

Explore the full profile